Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer
Dowling, Paul, Clarke, Colin, Hennessy, Kim, Torralbo-Lopez, Beatriz, Ballot, Jo, Crown, John, Kiernan, Ingrid, O'Byrne, Kenneth J., Kennedy, M. John, Lynch, Vincent, & Clynes, Martin (2012) Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. International Journal of Cancer, 131(4), pp. 911-923.
Early detection, clinical management and disease recurrence monitoring are critical areas in cancer treatment in which specific biomarker panels are likely to be very important in each of these key areas. We have previously demonstrated that levels of alpha-2-heremans-schmid-glycoprotein (AHSG), complement component C3 (C3), clusterin (CLI), haptoglobin (HP) and serum amyloid A (SAA) are significantly altered in serum from patients with squamous cell carcinoma of the lung. Here, we report the abundance levels for these proteins in serum samples from patients with advanced breast cancer, colorectal cancer (CRC) and lung cancer compared to healthy controls (age and gender matched) using commercially available enzyme-linked immunosorbent assay kits. Logistic regression (LR) models were fitted to the resulting data, and the classification ability of the proteins was evaluated using receiver-operating characteristic curve and leave-one-out cross-validation (LOOCV). The most accurate individual candidate biomarkers were C3 for breast cancer [area under the curve (AUC) = 0.89, LOOCV = 73%], CLI for CRC (AUC = 0.98, LOOCV = 90%), HP for small cell lung carcinoma (AUC = 0.97, LOOCV = 88%), C3 for lung adenocarcinoma (AUC = 0.94, LOOCV = 89%) and HP for squamous cell carcinoma of the lung (AUC = 0.94, LOOCV = 87%). The best dual combination of biomarkers using LR analysis were found to be AHSG + C3 (AUC = 0.91, LOOCV = 83%) for breast cancer, CLI + HP (AUC = 0.98, LOOCV = 92%) for CRC, C3 + SAA (AUC = 0.97, LOOCV = 91%) for small cell lung carcinoma and HP + SAA for both adenocarcinoma (AUC = 0.98, LOOCV = 96%) and squamous cell carcinoma of the lung (AUC = 0.98, LOOCV = 84%). The high AUC values reported here indicated that these candidate biomarkers have the potential to discriminate accurately between control and cancer groups both individually and in combination with other proteins. Copyright © 2011 UICC.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||acute-phase proteins, biomarkers, cancer, proteomics, biological marker, clusterin, complement component C3, fetuin A, haptoglobin, serum amyloid A, accuracy, adult, aged, analytic method, area under the curve, article, blood sampling, breast cancer, cancer staging, colorectal cancer, controlled study, disease marker, enzyme linked immunosorbent assay, female, human, leave one out cross validation, lung adenocarcinoma, lung cancer, lung small cell cancer, lung squamous cell carcinoma, major clinical study, male, priority journal, protein analysis, protein blood level, protein expression, receiver operating characteristic, sensitivity and specificity, Aged, 80 and over, alpha-2-HS-Glycoprotein, Breast Neoplasms, Colorectal Neoplasms, Complement C3, Enzyme-Linked Immunosorbent Assay, Haptoglobins, Humans, Logistic Models, Lung Neoplasms, Middle Aged, Serum Amyloid A Protein, Tumor Markers, Biological|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2012 John Wiley & Sons, Inc.|
|Deposited On:||02 Dec 2013 05:59|
|Last Modified:||18 Dec 2013 04:44|
Repository Staff Only: item control page